• Steven G DuBois, Laura B Corson, Kimberly Stegmaier, and Katherine A Janeway.
• Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
• Science. 2019 Mar 15; 363 (6432): 1175-1181.

AbstractCancer treatment decisions are increasingly based on the genomic profile of the patient's tumor, a strategy called "precision oncology." Over the past few years, a growing number of clinical trials and case reports have provided evidence that precision oncology is an effective approach for at least some children with cancer. Here, we review key factors influencing pediatric drug development in the era of precision oncology. We describe an emerging regulatory framework that is accelerating the pace of clinical trials in children as well as design challenges that are specific to trials that involve young cancer patients. Last, we discuss new drug development approaches for pediatric cancers whose growth relies on proteins that are difficult to target therapeutically, such as transcription factors.Copyright © 2019, American Association for the Advancement of Science.

21 keywords...

hide…